论文部分内容阅读
来自复旦大学上海医学院的研究人员在新研究中证实,基因TEKT4所发生的遗传变化与对乳腺癌化疗药物紫杉醇(paclitaxel)抵抗有关,相关论文发表在5月13日的Nature Communications杂志上。复旦大学上海医学院的邵志敏教授和余科达副教授是这篇论文的共同通讯作者。紫杉醇是一种具有抗肿瘤活性的天然产物,它通过诱导和促进癌细胞中微管的生成,阻止微管正常生理聚集来抑制癌细胞有丝分裂和纺锤体形成,致使快速分裂的癌细胞被限制在有丝分
Researchers from the Shanghai Medical College at Fudan University confirmed in a new study that the genetic changes that occur in the gene TEKT4 are associated with resistance to the chemotherapy drug paclitaxel in breast cancer, a paper published in the May 13 issue of Nature Communications. Shao Zhimin and Yu Keda, associate professor of Fudan University Shanghai Medical College, are the co-authors of this paper. Paclitaxel is a natural product with anti-tumor activity. It inhibits the mitosis and spindle formation of cancer cells by inducing and promoting the formation of microtubules in cancer cells and preventing the normal physiological aggregation of microtubules, resulting in the rapid division of cancer cells to be restricted to Silk marks